Thursday, July 14, 2022 Daily Archives

Solvias boosts CGT testing with Cergentis acquisition

by

Contract development firm Solvias has bought gene sequencing firm Cergentis to feed the expected growth in cell and gene therapy testing demand. The deal, financials of which have not been divulged, will see Swiss pharmaceutical testing and manufacturing firm Solvias absorb Utrecht, Netherlands-based Cergentis, bolstering its biologics and cell and gene therapy (CGT) testing solutions. Cergentis uses its genomic analysis platform for the characterization and QC of genetically engineered models, biopharmaceutical cell line development, and cell and gene therapy products.…

July 14, 2022

Emergent to make Ebola mAb for Ridgeback

by

Emergent BioSolutions will manufacture, sell, and distribute Ebanga (ansuvimab)  in the US and Canada through its partnership with Ridgeback Biotherapeutics. The deal, of which financial details have not been divulged, sees Emergent and Ridgeback Bio collaborate to expand the availability of Ebanga, which was approved by the US Food and Drug Administration (FDA) in December 2020 December 2020 to treat Ebola. Ebanga was developed to treat Ebola by Ridgeback Bio under license from the National Institute of Allergy and Infectious…

July 14, 2022

Cytiva bolsters resin operations outside of Sweden with Michigan plant buy

by

Cytiva has invested in additional resins production operations outside of Sweden for the first time through the acquisition of a facility from BASF in Muskegon, Michigan. While specific financial details of the acquisition remain undisclosed, Cytiva has acquired the Muskegon plant from German multinational chemical company BASF and said the chromatography resins facility is part of its $1.5 billion capacity expansion investment announced in July 2021. Cytiva plans to make the site into a 168,000 square-foot biomanufacturing center, which includes multiple…

July 14, 2022